IMRN - Immuron Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.59
-0.36 (-0.10%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close9.60
Open9.95
Bid0.01 x 1300
Ask10.15 x 1000
Day's Range9.30 - 9.95
52 Week Range4.63 - 16.70
Volume7,914
Avg. Volume6,261
Market Cap34.226M
Beta1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Could Immuron Limited’s (ASX:IMC) Investor Composition Impacts Your Returns?
    Simply Wall St.5 hours ago

    Could Immuron Limited’s (ASX:IMC) Investor Composition Impacts Your Returns?

    If you want to know who really controls Immuron Limited (ASX:IMC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in biggerRead More...

  • GlobeNewswire20 days ago

    US Department of Defense Reports Travelan Protects Against Shigella in Primates

    Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated NHPs compared to placebo. NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is pleased to provide shareholders with an update on the company’s cooperative research and development agreements with the US Department of Defense (US DoD).

  • GlobeNewswire2 months ago

    Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year

    Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17. US Travelan® sales continue to exceed expectations growing to AU$765k which represents a 114% increase over FY17. MELBOURNE, Australia, July 25, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the sales results of Travelan®, its commercially available, over-the-counter gastrointestinal and digestive health supplement, for the fiscal year ended June 30th, 2018.

  • GlobeNewswire2 months ago

    Immuron Announces it has Received a European Patent Grant for NASH treatment

    Immuron Limited (ASX:IMC) (IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company is pleased to announce that the European Patent Office (EPO) has decided to Grant a patent for the use of a composition for the treatment of Non-alcoholic steatohepatitis (NASH). This patent (EPO Grant No. 2424890) is entitled “Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder”).

  • GlobeNewswire2 months ago

    US Department of Defense Research Collaboration Moves Forward

    Three US Defense Health funded research projects on Travelan ® successfully completed Studies commissioned by the US Department of Defense to evaluate Travelan ®’ s ability to neutralise pathogenic bacteria ...